Amendment 1
Updated
A Word document (16 KB) attached to Senior Advisor 2 for Biological Therapeutics Development to act as External Oversight Committee (EOC) Subject Matter Expert (SME) Services., from the Office of the Assistant Secretary for Financial Resources (ASFR). Due Nov 5, 2026, 12:00 PM (UTC-5).
File name: Amendment 1.docx
The full file is for paid members, or buy this bid alone.
Preview
AMENDMENT 1
The purpose of this modification is to revise the number of anticipated award up to seven (7), to revise the number of hours to 50 hr./year WITH NO ADDITIONAL HOURS, to extend the due date for quotes, to revise technical evaluation factors and provide clarifications.
The Due Date for quotes is updated to November 5, 2026 at 12:00 pm EDT
The pricing template has been updated to reflect the revised number of hours with 50 hr./year WITH NO ADDITIONAL HOURS (see revised price schedule).
To replace technical evaluation factors with the revised attachment.
The estimated Period of Performance is revised as follows:. Base Period: November 13, 2026 – November 14, 2025
Option Period 1: November 13, 2027 – November 14, 2028
Option Period 2: November 13, 2029 – November 14, 2029
The Key Personnel should be available on the first day of the period of performance. 4. Questions: Key Personnel Employment Status. The solicitation requires proposed Key Personnel to be employed by the Quoter no later than the start of the period of performance, while Attachment 4 references the number of consultants proposed. Please confirm whether Key Personnel must be W-2 employees of the Quoter, or whether a consultant engaged under a written agreement with the Quoter would satisfy this requirement. Answer: The Key Personnel does not have to be a W-2 employee. This is a small business set aside and 50% of the work must be completed by a small business entity(ies). The Key Personnel should be available on the first day of the period of performance.
The beginning of the document. Download the full file to read on.